NEW YORK, Feb. 9 Reportlinker.com announces that a new market research report is available in its catalogue:
Acute Coronary Syndrome - Drug Pipeline Analysis and Market Forecasts to 2016
Advertisement
http://www.reportlinker.com/p0176371/Acute-Coronary-Syndrome---Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016.html
Acute Coronary Syndrome - Drug Pipeline Analysis and Market Forecasts to 2016
Advertisement
Summary
GlobalData, the industry analysis specialist's new report, "Acute Coronary Syndrome - Drug Pipeline Analysis and Market Forecasts to 2016" is an essential source of information and analysis on the global acute coronary syndrome market. The report identifies the key trends shaping and driving the global acute coronary syndrome market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global acute coronary syndrome sector.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData's team of industry experts.
Scope
The scope of the report includes:
- Annualized global acute coronary syndrome market revenues data from 2001 to 2009, forecast forward for 7 years to 2016.
- Geographic markets covered in this report include the US (United States), the UK (United Kingdom), Italy, Spain, Germany, France, and Japan.
- Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends.
- Analysis of the current and future market competition in the global acute coronary syndrome market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with acute coronary syndrome
Reasons to buy
The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global acute coronary syndrome market.
- Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global acute coronary syndrome market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What's the next big thing in the global acute coronary syndrome market landscape? - Identify, understand and capitalize.
1 Table of contents
1 Table of contents 2
1.1 List of Tables 4
1.2 List of Figures 4
2 Global Acute Coronary Syndrome: Market Characterization 5
2.1 Overview 5
2.2 Acute Coronary Syndrome Market Size 5
2.3 Acute Coronary Syndrome Market Forecast and CAGR 6
2.4 Drivers and Barriers for the Acute Coronary Syndrome Market 7
2.4.1 Drivers for the Acute Coronary Syndrome Market 7
2.4.2 Barriers for the Acute Coronary Syndrome Market 8
2.5 Opportunity and Unmet Need 8
2.6 Key Takeaway 10
3 Global Acute Coronary Syndrome Market: Competitive Assessment 11
3.1 Overview 11
3.2 Strategic Competitor Assessment 11
3.3 Product Profile for the Major Marketed Products in the Acute Coronary Syndrome Market 12
3.3.1 Lovenox (enoxaparin sodium injection) 12
3.3.2 Angiomax (bivaluridin, Angiox) 14
3.3.3 Integrilin (Eptifibatide) 16
3.3.4 Aggrastat (tirofiban hydrochloride) 17
3.3.5 Plavix (Clopidogrel bisulfate) 19
3.3.6 Effient (prasugrel) 20
3.4 Key Takeaway 22
4 Global Acute Coronary Syndrome Market: Pipeline Assessment 23
4.1 Overview 23
4.2 Strategic Pipeline Assessment 23
4.3 Acute Coronary Syndrome Market - Promising Drugs under Clinical Development 25
4.4 Molecule Profile for Promising Drugs under Clinical Development 25
4.4.1 Brilinta (ticagrelor) 25
4.4.2 Apixaban (BMS-562247-01) 26
4.4.3 Arixtra (fondaparinux) 26
4.4.4 RO4607381/R1658 27
4.4.5 MC-1 28
4.5 Acute Coronary Syndrome Market - Clinical Pipeline by Mechanism of Action 28
4.5.1 Acute Coronary Syndrome - Phase III Clinical Pipeline 29
4.5.2 Acute Coronary Syndrome - Phase II Clinical Pipeline 30
4.5.3 Acute Coronary Syndrome - Phase I Clinical Pipeline 31
4.5.4 Acute Coronary Syndrome - Preclinical Pipeline 31
4.5.5 Acute Coronary Syndrome - List of Terminated Clinical Trials 31
4.6 Key Take Away 32
5 Global Acute Coronary Syndrome Market: Implications for Future Market Competition 33
6 Global Acute Coronary Syndrome Market: Future Players 35
6.1 Introduction 35
6.2 GlaxoSmithKline 35
6.2.1 Company Overview 35
6.2.2 Business Description 35
6.3 Sanofi-Aventis 36
6.3.1 Company Overview 36
6.3.2 Business Description 36
6.4 Bristol-Myers Squibb Company 37
6.4.1 Company Overview 37
6.4.2 Business Description 38
6.5 AstraZeneca 38
6.5.1 Overview 38
6.5.2 Business Description 39
6.6 Daiichi Sankyo Co. Ltd 40
6.6.1 Company Overview 40
6.6.2 Business Description 40
6.7 Pfizer Inc. 41
6.7.1 Company Overview 41
6.7.2 Business Description 42
7 Acute Coronary Syndrome Market: Appendix 44
7.1 Definitions 44
7.2 Acronyms 44
7.3 Research Methodology 45
7.3.1 Coverage 46
7.3.2 Secondary Research 46
7.3.3 Forecasting 46
7.3.4 Primary Research 49
7.3.5 Expert Panels 49
7.4 Contact Us 49
7.5 Disclaimer 49
7.6 Sources 50
1.1 List of Tables
Table 1: Acute Coronary Syndrome, Global, Historical Revenue ($m), 2001-2009 6
Table 2: Acute Coronary Syndrome, Global, Forecasted Revenue ($m), 2009-2016 7
Table 3: Major Marketed Products Comparison in Acute Coronary Syndrome Market, 2010 22
Table 4: Acute Coronary Syndrome - Most Promising Drugs Under Clinical Development, 2010 25
Table 5: Acute Coronary Syndrome Therapeutics - Phase III Clinical Pipeline, 2010 29
Table 6: Acute Coronary Syndrome Therapeutics - Phase II Clinical Pipeline, 2010 30
Table 7: Acute Coronary Syndrome - Phase I Clinical Pipeline, 2010 31
Table 8: Acute Coronary Syndrome - Preclinical Pipeline, 2010 31
Table 9: Acute Coronary Syndrome - List of Terminated Clinical Trials, 2010 31
Table 10: GlaxoSmithKline - Cardiovascular and Acute Coronary Syndrome Pipeline Product Portfolio, 2010 36
Table 11: Sanofi-Aventis - Cardiovascular and Acute Coronary Syndrome Pipeline Product Portfolio, 2010 37
Table 12: Bristol-Myers Squibb - Cardiovascular and Acute Coronary Syndrome Pipeline Product Portfolio, 2010 38
Table 13: AstraZeneca - Cardiovascular and Acute Coronary Syndrome Pipeline Product Portfolio, 2010 40
Table 14: Daiichi Sankyo - Cardiovascular and Acute Coronary Syndrome Pipeline Product Portfolio, 2010 41
Table 15: Pfizer Inc - Cardiovascular and Acute Coronary Syndrome Pipeline Product Portfolio, 2010 43
1.2 List of Figures
Figure 1: Acute Coronary Syndrome, Global, Historical Revenue ($m), 2001-2009 6
Figure 2: Acute Coronary Syndrome, Global, Forecasted Revenue ($m), 2009-2016 7
Figure 3: Opportunity and Unmet Need in the Acute Coronary Syndrome Market, 2010 9
Figure 4: Strategic Competitor Assessment, 2010 11
Figure 5: Pipeline Products by Phase of Development, 2009 23
Figure 6: Technology Trends Analytics Frame Work, 2010 24
Figure 7: Technology Trends Analytics Frame Work - Description, 2010 24
Figure 8: Acute Coronary Syndrome Market - Clinical Pipeline by Mechanism of Action, 2010 28
Figure 9: Acute Coronary Syndrome Market - Clinical Pipeline by Phase of Development, 2010 29
Figure 10: Implications for Future Market Competition in the Acute Coronary Syndrome Market, 2010 33
Figure 11: Acute Coronary Syndrome Market - Clinical Pipeline by Company, 2010 35
Figure 12: GlobalData Methodology 45
Figure 13: GlobalData Market Forecasting Model 48
Companies Mentioned
GlaxoSmithKline
Sanofi-Aventis
Bristol-Myers Squibb Company
AstraZeneca
Daiichi Sankyo Co.Ltd
Pfizer Inc.
To order this report:
Drug and Medication Industry: Acute Coronary Syndrome - Drug Pipeline Analysis and Market Forecasts to 2016
More Market Research Report
Check our Company Profile, SWOT and Revenue Analysis!
Contact: Nicolas Bombourg Reportlinker Email: [email protected] US: (805)652-2626 Intl: +1 805-652-2626
SOURCE Reportlinker
